Early Detection Programs May Help Offset Costs of COPD Exacerbations, Studies Find
May 21st 2020Exacerbations of patients with chronic obstructive pulmonary disorder (COPD) can be costly if they are frequent, and early detection programs for COPD may help offset these costs, according to research from 2 studies presented at the 2020 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) virtual conference.
Read More
Studies Outline Asthma's Economic Toll
May 21st 2020Although the total cost of asthma was more than $80 billion in 2013, the expansion of Medicaid in 2014 aided patients with asthma, according to 2 studies presented at the 2020 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) virtual conference.
Read More
Linking Opportunity Costs and Value Assessments for State and Commercial Payers
May 20th 2020When deciding which treatments to cover, states and commercial payers must wrestle with opportunity costs as new therapeutics come to market. A panel at Virtual ISPOR 2020 discussed some of the factors that go into those decisions.
Read More
In 2 abstracts presented at the Virtual ISPOR 2020 meeting, researchers discuss how “OFF” episodes among patients with Parkinson disease may contribute to an increased degree of burden for respective caregivers, with patient preferred on-demand treatments for these episodes also detailed.
Read More
Virtual ISPOR Panel to Examine Next Steps in Value Assessment
May 18th 2020Two of the panelists appearing during the Virtual ISPOR 2020 meeting preview what's needed in improving value assessment: Lou Garrison, PhD, of the University of Washington, and Leah Howard, JD, of the National Psoriasis Foundation.
Read More
Dr Nicholas Robert Outlines How Patients Can Provide More Information on Newly Approved Drugs
August 22nd 2019Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, discusses how patient-reported outcomes collected through real-world data can provide confirmatory information on newly approved drugs.
Read More
Dr Nicholas Robert: Lag Time Between a Drug Approval, Availability in EMRs Can Impact Patient Care
August 10th 2019Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, explains the impact of lag time between a drug's approval and its availability for use in the electronic medical record (EMR).
Read More
Dr Nicholas Robert on Lag Time Between Drug Approval, Availability of the Drug in EMRs
July 29th 2019Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, discusses the lag time between a drug's approval and its availability in the electronic medical record (EMR) for the physician to order.
Read More
Dr Eleanor Perfetto on Ways to Improve Transparency, Education Around Value Assessment
July 23rd 2019Eleanor M. Perfetto, PhD, MS, senior vice president of Strategic Initiatives for the National Health Council, discusses potential strategies for increasing transparency in value assessment and where education fits into the mix.
Read More
Dr Nicholas Robert Discusses How Real-World Data Can Complement Clinical Trial Data
July 16th 2019With real-world data, there's an opportunity to take a new agent and see how patients outside that clinical trial would do, explained Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences.
Read More
Dr Devin Incerti: Use Value Assessments to Maximize the Well-Being of a Population
July 14th 2019If you set social benefits equal to social costs, you will be able to maximize the well-being of a population, and that's what value assessment allows for, explained Devin Incerti, PhD, lead economist, Innovation and Value Initiative.
Read More
Dr Nicholas Robert Explains the Need to Standardize Use of RWE for Measuring Clinical End Points
June 23rd 2019Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, discusses the need for standardizing the use of real-world evidence for measuring endpoints in clinical practice.
Read More
Dr Jon Campbell on Benefits of Using MCDA in Value Assessment
June 3rd 2019Jonathan Campbell, PhD, associate professor, Department of Clinical Pharmacy, Pharmaceutical Outcomes Research, Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado, discusses the value of multi-criteria decision analysis (MCDA) in value assessment, as well as lessons learned from using MCDA in other industries.
Read More
Fremanezumab Cost Effective for Both Types of Migraine, Researchers Say
May 27th 2019A computer simulated cost-effectiveness model of fremanezumab for migraine found that it was cost effective versus no treatment. Researchers presented a poster about its cost-effectiveness for the prevention of chronic and episodic migraine at ISPOR 2019.
Read More
New Therapies Offer Possible Cures but Pose Affordability Challenges
May 23rd 2019The upfront prices of potentially curative therapies are terrifying to commercial payers and government payers alike. A panel on the last day of ISPOR 2019 discussed these issues in a session called, “Is Affordability Driving a Need to Revolutionize Drug Pricing?”
Read More
Dr Eleanor Perfetto Outlines Criticisms of the QALY
May 23rd 2019Eleanor M. Perfetto, PhD, MS, senior vice president of Strategic Initiatives for the National Health Council, discusses criticisms of the quality-adjusted life year (QALY) and what factors the measure does not take into account.
Read More
Dr Nicholas Robert Explains the Benefits, Challenges of Using RWE for Measuring Clinical End Points
May 23rd 2019Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, discusses the benefits of real-world evidence (RWE) for measuring end points, as well as the challenges posed by variability in clinical practice.
Read More
Panelists Debate the Role of ICER: Useful Overseer of Prices, or Oppressor of Choice?
May 22nd 2019Representatives from different parts of the healthcare system, as well as an outside observer, weighed in on whether the reports issued by the Institute for Clinical and Economic Review (ICER) are taking away patient choice.
Read More
Paul Melmeyer: Value Assessments Need to Take Into Account Unique Characteristics of a Disease
May 22nd 2019It is incredibly important for these assessments to consider the context of the therapy, rather than just the clinical benefit that it brings, explained Paul Melmeyer, director of Federal Policy, National Organization for Rare Disorders.
Read More
Dr Jon Campbell Discusses the Need for More Creative Methods of Value Assessment
May 21st 2019Jonathan Campbell, PhD, associate professor, Department of Clinical Pharmacy, Pharmaceutical Outcomes Research, Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado, discusses the need for more creative methods for value assessment, as well as how one-time, high-cost therapies make it harder to determine value.
Read More
Panelists Discuss the Potential and Pitfalls of Disruption in Healthcare
May 21st 2019Medical futurist Daniel Kraft, MD, implored his audience of healthcare stakeholders attending the ISPOR 2019 annual conference to consider the different ways that technology disruption can improve care away from what he called “sick care,” while moderator Clifford Goodman, PhD, of The Lewin Group, moderated a panel that followed about the potential and pitfalls of disruption in healthcare.
Read More
Dr Harlan Krumholz on Barriers Preventing Healthcare From Using Data to Improve Care
August 1st 2018The free flow of data needs to be an intrinsic part of the way we think about healthcare in this country, said Harlan Krumholz, MD, SM, the Harold H. Hines Jr professor, Medicine and Epidemiology and Public Health, Yale School of Medicine, and director, Center for Outcomes Research and Evaluation, Yale-New Haven Hospital.
Read More